North American Leukemia, Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy, and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906)
Year: 2015
Type: article
Study design: Clinical Trial
Source: Blood
Authors: James M. Foran, Zhuoxin Sun, David F. Claxton, Hillard M. Lazarus, Mary L. Thomas, Ari Melnick, Ross L. Levine, Elisabeth Paietta, Daniel Arber, Yangming Zhang, Jacob M. Rowe, John E. Godwin, Jessica K. Altman, Selina Luger, Aref Al-Kali, Hong Zheng, Keith Pratz, E. Randolph Broun, Bayard L. Powell, Kristen O'Dwyer, Mark R Litzow, Martin S Tallman
Institutions: Mayo Clinic, Mayo Clinic in Florida, Dana-Farber Cancer Institute, Penn State Cancer Institute, University Hospitals of Cleveland, University Hospitals Cleveland Medical Center, Case Western Reserve University, VA Palo Alto Health Care System, Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center, Stanford Medicine, Stanford University, Northwestern University, Shaare Zedek Medical Center, Bikur Cholim Hospital, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Abramson Cancer Center, University of Pennsylvania, Pennsylvania State University, Penn State Milton S. Hershey Medical Center, Sidney Kimmel Comprehensive Cancer Center, Jewish Hospital, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University, University of Rochester Medicine, University of Rochester
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2528446701